Antimicrobial Susceptibility Test Market

Antimicrobial Susceptibility Test Market Size and Share Forecast Outlook 2025 to 2035

The global antimicrobial susceptibility test market is projected to increase from USD 3.8 billion in 2025 to USD 8.3 billion by 2035, with a CAGR of 8.1% during the forecast period. The antimicrobial susceptibility test market is growing due to rising antimicrobial resistance, increasing prevalence of infectious diseases, and the demand for rapid, accurate diagnostic tools. Hospitals and clinical laboratories increasingly rely on these tests to guide effective treatment and improve patient outcomes.

Quick Stats of Antimicrobial Susceptibility Test Market

• Antimicrobial Susceptibility Test Market Size (2025): USD 3.8 billion
• Projected Antimicrobial Susceptibility Test Market Size (2035): USD 8.3 billion
• Forecast CAGR of Antimicrobial Susceptibility Test Market (2025 to 2035): 8.1%
• Leading Test Type Segment of Antimicrobial Susceptibility Test Market: Automated
• Leading End-Use Segment of Antimicrobial Susceptibility Test Market: Hospitals
• Key Growth Regions of Antimicrobial Susceptibility Test Market: United Kingdom, South Korea, India
• Prominent Players in the Antimicrobial Susceptibility Test Market: Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, and Others.

The global Antimicrobial Susceptibility Test market is forecast to expand from USD 3.8 billion in 2025 to USD 8.3 billion by 2035, at a CAGR of 8.1%, driven by strong demand resulting from the rising incidence of hospital-acquired infections (HAIs) and the growing threat of antimicrobial resistance (AMR).

According to the World Health Organization, approximately 136 million HAIs occur worldwide each year, with 119 million reported in low- and middle-income countries. In the United States, the CDC estimates that one in every 31 hospital patients experience at least one HAI on any given day, emphasizing the importance of accurate AST solutions to guide effective antimicrobial treatment.

The market is expected to grow steadily from USD 3.8 billion in 2025 to USD 4.1 billion in 2026, USD 4.5 billion in 2027, USD 4.8 billion in 2028, USD 5.2 billion in 2029, and USD 5.6 billion in 2030, as hospitals and diagnostic laboratories adopt automated and high-throughput testing systems.

From 2031 to 2035, the market continues to grow, reaching USD 6.1 billion in 2031, USD 6.6 billion in 2032, USD 7.1 billion in 2033, USD 7.7 billion in 2034, and USD 8.3 billion in 2035, aided by technological advancements, rapid diagnostics, and global AMR awareness campaigns.

Government and organizational initiatives are hastening adoption, with policies promoting standardized testing protocols, HAI monitoring, and rapid antimicrobial resistance identification. Rising healthcare costs, combined with the integration of advanced AST platforms and a greater emphasis on infection control, are establishing the AST market as a critical component of modern clinical diagnostics worldwide.

Key Antimicrobial Susceptibility Test Market Dynamics

The global Antimicrobial Susceptibility Test (AST) market is expanding rapidly, driven primarily by the rising prevalence of infectious diseases and the growing threat of antimicrobial resistance (AMR), which necessitates the precise identification of effective treatments. The growing demand for rapid and accurate diagnostics is driving market growth as healthcare providers and laboratories strive to improve patient outcomes while reducing antibiotic misuse.

However, the market faces significant challenges, including the high cost of advanced testing equipment, which may limit adoption in resource-constrained environments. Furthermore, a shortage of skilled laboratory personnel in certain regions, as well as stringent regulatory approvals and compliance requirements, may stifle market growth, necessitating strategic investment in training and regulatory navigation.

Rising Prevalence of Infectious Diseases

The global rise in infectious diseases, such as bacterial, fungal, and viral infections, is a significant driver of the AST market. Healthcare facilities require precise testing to identify pathogens and determine their susceptibility to specific antibiotics. AST enables clinicians to select the most effective treatment, thereby improving patient outcomes and reducing complications.

In areas with high rates of hospital-acquired infections or multidrug-resistant organisms, routine susceptibility testing has become essential. The growing disease burden has directly increased the demand for AST devices and consumables in clinical and diagnostic laboratories worldwide.

Increasing Antimicrobial Resistance (AMR)

Antimicrobial resistance is a growing global health concern, making standard antibiotic therapies ineffective. AST aids healthcare providers in identifying resistant strains, allowing for targeted treatment and reducing the use of broad-spectrum antibiotics.

The World Health Organization and the CDC have identified AMR as a top health priority, prompting governments and hospitals to tighten infection control and diagnostic protocols. The growing awareness of AMR among healthcare professionals and policymakers has led to an increased adoption of AST systems. This trend is especially noticeable in areas with high rates of drug-resistant infections, which fuels continued market growth.

Growing Demand for Rapid and Accurate Diagnostics

Healthcare providers are increasingly seeking quick and precise diagnostic tools to improve patient care. Rapid AST systems allow for the timely determination of pathogen susceptibility, minimizing treatment initiation delays. These systems also help to prevent the spread of resistant infections in hospitals and communities.

Innovations in automated, high-throughput AST platforms, as well as integration with digital laboratory solutions, have increased testing efficiency. The adoption of personalized medicine approaches, where selecting the right antibiotic is critical for effective patient management, is driving up the demand for accurate diagnostics even more. As a result, the demand for rapid and dependable AST solutions is a major growth driver.

High Cost of Implementation

Advanced AST platforms, such as automated and high-throughput systems, necessitate significant upfront investment in terms of acquisition, maintenance, and consumable costs. This high cost restricts access to smaller clinics, laboratories, and healthcare facilities in developing countries. Hospitals with limited budgets may continue to use traditional, manual testing methods, which can slow market penetration.

Furthermore, operational expenses for calibration, quality control, and software updates add to the financial burden. While these systems produce faster and more accurate results, cost remains a significant barrier, particularly in low- and middle-income countries with a high infectious disease burden but limited resources.

Lack of Skilled Laboratory Personnel in Some Regions

AST requires trained microbiologists and laboratory technicians who can correctly interpret results and maintain quality standards. In many areas, there is a scarcity of such skilled professionals, which can lead to testing delays and reduced diagnostic accuracy.

The lack of expertise is particularly evident in rural or resource-constrained settings, where laboratories may struggle to implement automated or advanced AST technologies. This human resource constraint limits market growth because healthcare facilities may be hesitant to invest in sophisticated systems that require trained personnel to operate them. Training programs and workforce development initiatives are required to meet this challenge.

Stringent Regulatory Approvals and Compliance Requirements

AST devices are subject to stringent regulatory oversight to ensure their safety, dependability, and clinical accuracy. Obtaining approval from authorities such as the FDA, CE, or other national regulatory bodies can be time-consuming and expensive, potentially delaying product launches.

Furthermore, manufacturers' operational complexity increases as they continue to adhere to laboratory standards and quality control procedures. These regulatory barriers may deter new entrants or impede the adoption of innovative AST technologies. The need to navigate complex approval pathways while adhering to local and international guidelines remains a significant barrier, especially for smaller companies looking to expand globally.

Analyzing the Antimicrobial Susceptibility Test Market by Key Regions

North America dominates the antimicrobial susceptibility testing market, primarily due to its advanced healthcare infrastructure, significant investments in research and development, and a high adoption rate of advanced diagnostic technologies. The United States, in particular, is a significant contributor to the market, thanks to its well-established healthcare system and strong emphasis on combating antimicrobial resistance.

Europe is another important market for antimicrobial susceptibility testing, driven by the same factors as North America. The region adopts a proactive approach to antimicrobial resistance, supported by stringent regulatory guidelines and extensive research activities. Germany, the United Kingdom, and France are major market contributors, largely due to their well-established healthcare systems and substantial R&D investments.

The Asia Pacific region is expected to have the fastest growth rate in the antimicrobial susceptibility testing market during the forecast period. This increase is due to rising healthcare spending, increased awareness of antibiotic resistance, and the rapid expansion of healthcare infrastructure in emerging economies. Countries like China, India, and Japan are major market contributors, having made significant investments in modernizing their healthcare systems.

Country-Wise Outlook

United Kingdom’s Growing Demand for AST Driven by AMR Strategies and Rising Infections

The antimicrobial susceptibility testing (AST) market in the United Kingdom is expanding rapidly, due to a variety of factors. The UK's 2024-2029 National Action Plan on Antimicrobial Resistance (AMR) emphasises the importance of optimising antimicrobial use, improving diagnostics, and promoting the development of new therapies.

This strategic approach is expected to increase demand for advanced AST solutions in clinical settings. The rising prevalence of hospital-acquired infections and multidrug-resistant pathogens is adding to the demand for effective AST methods.

In response to these challenges, the UK government has launched novel approaches to combat AMR. A notable example is the NHS's subscription-based model for antibiotics, in which pharmaceutical companies are paid up to £20 million per year per drug, regardless of the quantity prescribed. This initiative aims to encourage the development of new antibiotics while discouraging overuse.

Furthermore, the UK is investing in research collaborations to address AMR in environmental settings, recognizing the importance of a comprehensive approach to combating this global health threat. These efforts are expected to accelerate the development of AST technologies and increase their adoption in UK healthcare facilities.

However, the UK's fight against AMR is not without challenges. Despite the implementation of various strategies, the National Audit Office reports that AMR causes over 35,200 deaths per year in the UK, with a 13% increase in drug-resistant infections since 2018. This emphasizes the importance of continued investment in AST infrastructure and the development of innovative diagnostic solutions to effectively combat antimicrobial resistance.

• UK policies and NHS model boost AST demand
• Drug-resistant infections increase AST adoption
• AMR causes 35,000+ deaths, stressing diagnostic investment

South Korea's Antimicrobial Susceptibility Test Market Thrives on Rising Infection Rates and Advancements in Diagnostic Technologies

South Korea's antimicrobial susceptibility testing (AST) market is expanding steadily, driven by strategic government initiatives, rising infection rates, and advancements in diagnostic technologies. The growing awareness of antimicrobial resistance (AMR) and the need for precise treatment decisions is driving healthcare facilities to adopt advanced AST solutions.

The South Korean government has implemented a comprehensive National Action Plan on AMR, emphasizing the prudent use of antimicrobials and improving diagnostic capabilities. Several agencies, including the Ministry of Health and Welfare and the Korea Disease Control and Prevention Agency, are working together under a One Health approach to effectively combat AMR in human, animal, and environmental health.

Hospital-acquired infections and multidrug-resistant pathogens continue to pose significant challenges in the country. The rising prevalence of resistant strains, such as multidrug-resistant Pseudomonas aeruginosa, emphasizes the importance of AST in guiding effective antimicrobial therapy and improving patient outcomes.

• Government AMR initiatives drive AST adoption
• Rising drug-resistant infections increase testing demand
• Advanced diagnostics enhance treatment accuracy

India Advances in Antimicrobial Susceptibility Test Market with Focus on Combination of Government Initiatives

India's antimicrobial susceptibility testing (AST) market is expanding rapidly, driven by a combination of government initiatives, rising infection rates, and advancements in diagnostic technologies.

The National Action Plan on Antimicrobial Resistance (NAP-AMR), which was released in 2017, emphasizes the importance of improving diagnostics, optimizing antimicrobial use, and encouraging the development of new treatments. This strategic approach is expected to drive up demand for advanced AST solutions in clinical settings. The National Programme on AMR Containment also promotes the development of laboratory-based AMR surveillance systems and the improvement of infection control practices.

The rising prevalence of hospital-acquired infections and multidrug-resistant pathogens increases the need for effective AST methods. Studies have shown an increase in the number of infections caused by resistant strains, such as multidrug-resistant Pseudomonas aeruginosa, which pose challenges to treatment and patient outcomes. These trends underscore the importance of effective antimicrobial susceptibility testing in guiding appropriate therapy.

Technological advancements are influencing the AST market in India. The use of artificial intelligence (AI) and machine learning (ML) in AST systems improves diagnostic accuracy and reduces turnaround times. These technologies analyze large-scale clinical and genomic datasets to detect resistance patterns and recommend effective treatment options. This innovation represents a shift away from traditional, time-consuming AST methods and toward AI-driven systems that speed up clinical microbiology decision making.

• Government initiatives like NAP-AMR and AMR containment programs boost AST adoption
• Rising hospital-acquired infections and multidrug-resistant pathogens drive demand
• AI and ML integration in AST systems enhances precision and reduces turnaround times

Category-wise Analysis

Automated Testing Driving Market Growth Through Efficiency and Accuracy in Testing

In 2025, the automated test integration sector is expected to account for 30% of total revenue. Several key factors contribute to the significant growth of the automated products segment in the Antimicrobial Susceptibility Testing (AST) market. Automation offers benefits such as increased testing throughput, improved accuracy, and faster results compared to manual methods.

In an era where timely treatment decisions are crucial in combating antibiotic resistance, automated products streamline the testing process, enhancing efficiency and minimising human error. They also follow the trend of integrated and automated diagnostic solutions in the healthcare industry. As a result, healthcare facilities are increasingly implementing automated AST systems, fueling the segment's significant market growth.

• Automation boosts testing speed, accuracy, and efficiency
• Reduces human error in antimicrobial susceptibility testing
• Supports timely treatment decisions, driving adoption in healthcare facilities

Hospitals are a Key Segment Driving Growth Due to Rising Infection Management Needs

The hospitals segment expanded rapidly, accounting for 50.0% of revenue, owing to hospitals' critical role in diagnosing and treating infections, particularly those caused by multidrug-resistant pathogens. Due to the large number of patients who require bacterial infection diagnosis and treatment, hospitals are expected to remain the primary users of antimicrobial susceptibility testing services.

As hospitals expand their infectious disease management programs and diagnostic capabilities, demand for antimicrobial susceptibility testing is expected to grow. The rising prevalence of hospital-acquired infections, along with the growing emphasis on infection prevention and control strategies, is expected to drive market growth in this segment.

Furthermore, increasing awareness of the importance of precise antibiotic stewardship in hospital settings is likely to drive the continued use of antimicrobial susceptibility testing in hospitals.

• Hospitals lead AST market with 50% revenue
• Rising infection management drives AST demand
• Focus on antibiotic stewardship boosts usage

Competitive Analysis

The antimicrobial susceptibility testing market is highly competitive, with numerous players vying for market share. The competitive landscape is characterized by the presence of both established and emerging companies, all of which are striving to develop innovative products and increase their market presence. The market is also witnessing a trend of strategic collaborations, mergers, and acquisitions as businesses seek to expand their product portfolios and gain a competitive edge.

Key market players are investing heavily in R&D to introduce advanced susceptibility testing methods and automated laboratory instruments, which will drive market growth and maintain their competitive positions.

Becton, Dickinson and Company (BD) is a major player in the antimicrobial susceptibility testing market. BD is a leading global medical technology company that provides a diverse range of diagnostic products, including antimicrobial susceptibility testing systems. The company is recognised for its innovative products, including the BD Phoenix™ Automated Microbiology System, which delivers rapid and accurate susceptibility testing results. BD's strong focus on R&D, combined with its extensive global presence, has helped it maintain a dominant market position.

Key Players in the Market

• Bio-Rad Laboratories Inc.
• Beckman Coulter Inc.
• Thermo Fisher Scientific Inc.
• Conda
• Creative Diagnostics
• BD (Becton Dickinson)
• HiMedia Laboratories
• Alifax Holding S.p.A.
• Biotron Healthcare.
• bioMérieux
• Danaher Corporation

Recent Developments

• In March 2025, bioMérieux's VITEK® COMPACT PRO system received 510(k) clearance from the U.S. FDA. This integrated system for microorganism identification and antibiotic susceptibility testing (AST) is intended for use in both clinical and industrial laboratories. It supports infection diagnosis and efforts to address antimicrobial resistance by delivering faster, more precise, and consistent results than earlier VITEK® models.
• In April 2025, The FDA granted 510(k) clearance for Becton Dickinson’s BD Phoenix M50 combined with the BDXpert System within the BD Synapsys Informatics suite. It incorporates advanced algorithms to interpret microbial identification (ID) and AST data, enhancing lab efficiency and speeding the delivery of accurate, clinically actionable results.